Value frameworks scoring of a new oncology treatment and comparators

What is market access?

For pharmaceutical and biotechnology manufacturers, enabling faster patient access to therapies is a key challenge. An effective market access strategy helps them solve the challenge.   Market access: a basic definition In the simplest terms, market access is about getting the right treatment to the right patient at the right time, and possibly even at …

Indication-based pricing: your free eBook download

Optimize the value of assets in development across multiple indications

Achieving a variable price by indication: free eBook download

Achieve a variable price by indication

PRMA Consulting Expert Advisory Group on Complex Pricing (EAGCP): Focus on gene therapies

A recent meeting of complex pricing experts focused on the challenges and solutions for pricing and reimbursement in the area of innovative cell and gene therapy products. The bespoke group shared knowledge from a range of countries and different roles within healthcare systems, to bring a practical and pragmatic approach to issues related to pricing. …

Digitally transforming health technology assessment (HTA) submission processes

Evaluate how digital technology can better enable processes and requirements

Over the last few years we have seen how digital technology has been harnessed to improve health outcomes. With the rapidly evolving market access landscape, we are now on the cusp of a huge acceleration in the use of digital applications to explore value options, gain strategic advantage and provide innovative market access solutions. To …

Using payer perspectives to inform evidence generation strategies for successful market access

Recommendations for an ophthalmology launch plan in the EU

Transforming the market access landscape: the role of digital applications

Pharmaceutical and biotechnology companies are turning to technology more frequently to solve business issues, and are increasingly using digital technology to optimize market access for their products.

Clarity or confusion: the role of value frameworks in oncology

This on-demand webinar uses case studies to illustrate key concepts in the emerging role of value frameworks in oncology.

Exploring the challenges for pricing and reimbursement of high-cost combination therapies

Gain market access insight from payer and pricing experts from across the EU into: the reimbursement mechanisms for combination products the access challenges these mechanisms present for new innovative combinations the scope for potential solutions the policy direction in France, Germany, and the UK

Strategic and tactical support achieves HTA success

Strategic projects to inform commercialization decisions in RSV

Biosimilars: market access considerations

As the biosimilar market expands, payers are looking to take advantage of potential budget savings.

Landscape assessments and market access strategy for CDx-drug pairings

Accelerating decision-making for international market access

Does 1+1 always equal 2? Valuing combinations

With more drugs coming to market, and the growing number of possible combinations, this on-demand webinar discusses how combinations of drugs are evaluated by payers.

Patient-centricity: a crucial approach for market access?

As the focus of healthcare providers shifts to placing patients at the center of their activities, it is important for the pharmaceutical industry to adopt more patient-centric ways of working.

Designing effective managed entry agreements: insight from Spain

A recent meeting of complex pricing experts from across the EU5 countries focused on the variability among countries of payers’ and policy-makers’ attitudes to MEAs, and the practical challenges for implementation capable of satisfying a range of country requirements. Here we summarize the insights from the Spanish discussion. Budget caps are still the most common …

Strategic roadmap for optimized global market access for CAR-T

Market access for PD-1 inhibitors: where are we now?

This on-demand webinar shares our thoughts on evaluations for PD-1 inhibitors and assess some of the implications for manufacturers.

Recommendations for successfully developing managed entry agreements

A recent meeting of complex pricing experts from across the EU5 countries (France, Germany, Italy, Spain, and the UK) focused on the variability among countries of payers’ and policy-makers’ attitudes to managed entry agreements (MEAs), and the practical challenges for implementation capable of satisfying a range of country requirements. Here we summarize the insights from …

Review of CAR-T assessments and implications for novel agents

Bolstering payer discussions to solve persistent challenges

Five strategies for CAR-T pricing and reimbursement success

CAR-T therapy: the future begins to take shape

Managed entry agreements: regional and national insight

Managed entry agreements: theory and principles

Achieving a positive HTA outcome with insight from payer and clinician advisory boards

Assessing evidence generation strategies for an asset with a novel biomarker in a rapidly evolving landscape

Exploring the challenges for pricing and reimbursement of high-cost combination therapies

Gain market access insight from payer and pricing experts from across the EU into:

Anticipate evidence needs early on and accelerate development of focused evidence generation activities

Patient-centricity: shaping value generation for HTA and market access

This webinar focuses on different European patient engagement models and guidelines. It also provides insight into how to shape value from an HTA and market access perspective.

Four recommendations to kick-start the digital transformation of your market access processes

Darren McBride shares his experience of digital transformation in pharmaceutical and biotechnology market access, and makes four recommendations for those who are keen to drive change.

Protect your market access data: the value of ISO27001

In this market access update, Darren McBride summarizes the importance of reviewing your supplier’s information security standards.

Identifying critical risks for payer decision-making

Case studies

Protecting your market access data. 10 questions to ask your suppliers

Suppliers who provide you with software-as-a-service (SaaS) need to gather, analyze, and transfer market access data on your behalf. You may send data to them, or upload directly to their application. To avoid business risks, it is essential to understand how the supplier manages your data, and how they are protected, handled, stored, and retained …

Exploring the benefits of cloud computing for market access.

In a couple of sentences, what is cloud computing? Cloud computing provides pooled resources and services via the internet to users, on-demand, 24/7. At PRMA Consulting we capitalize on cloud services to transform the market access process of leading pharmaceutical and biotechnology companies. How is cloud different to the traditional data centers that market access …

Top-5 pharma discovers a new way to evaluate pricing opportunities

Critically evaluating pricing and access risks and opportunities for an asset under different clinical development scenarios

Measuring survival benefit in oncology health technology assessments

Immuno-oncologic therapies have frequently produced unorthodox survival profiles, particularly when compared with cytotoxic chemotherapy drugs. Delayed onset of treatment effect, “pseudo-progression”, subgroups of durable responders, bridging to curative therapy, and other pronounced forms of heterogeneity of efficacy are potential contributors to this. In these circumstances, the conventional toolkit for measuring survival benefit, established when cytotoxic …

Blocking competitor intrusion in competitive pharmaceutical markets

Market access considerations for CAR-Ts: insights from ASH

This on-demand webinar reviews key learnings from the 2017 ASH annual meeting.

Managed entry agreements: regional and national insight

Managed entry agreements: theory and principles

Demonstrating value using a new approach to economic modeling

CLIENT SITUATION Using the PRMA Healthcheck® late module, a top-20 pharmaceutical company quickly identified an opportunity to engage with HTA agencies and an expert technical panel in their exploration of potential approaches to cost-effectiveness modeling.

Improve health technology assessment submissions

Achieve up to 80% auto-population of your first draft submission

Pricing and reimbursement of CAR‐T in Germany

CAR-T therapy: the future begins to take shape

Incorporating the patient voice in market access

The patient voice is firmly established as key to determining value in healthcare. This means that pharmaceutical and biotechnology manufacturers should evaluate and evolve how they engage with patients.

Combinations: P&R considerations

Evidence synthesis and development of economic models

Improving pharmaceutical portfolio management and decision-making for early assets

Learn how this top-10 company refined its portfolio management strategy for pre-clinical assets. Capitalizing on the latest digital technology in the pharmaceutical industry, it successfully restructured market access frameworks and prioritized investment decisions.

Payer perspectives on cell and gene therapies: opportunities and challenges

In this on-demand webinar, Professor Stephen Palmer from the University of York discusses his work on the assessment of regenerative medicines and cell therapy, and the UK and EU payer perspective on the potential value of these therapies.

The relevance of patient perspectives to value

In the first of her two-part series, Sarah Richard explores the evolution of patient involvement in health technology assessment, and the role of the patient voice in market access.

Creating compelling real-world evidence that supports favorable HTA

Indication-specific pricing: the obvious solution

This on-demand webinar examines the challenges and opportunities for manufacturers and payers in implementing an indication-specific pricing strategy.

Potential solutions for pricing and reimbursement of high-cost combination products

Pricing and reimbursement solutions for high-cost combination therapies

Exploring the challenges for pricing and reimbursement of high-cost combination therapies

Gain market access insight from payer and pricing experts from across the EU into:

Pricing and reimbursement in Canada: a market access update

Here’s our round up of healthcare market access news from Canada over recent months.

Developing a market access and HEOR roadmap in a rapidly evolving landscape

Maximize the pricing and market access potential of your early pipeline

Championing digital transformation within biotech and pharma companies

Supporting clients through the challenges and opportunities presented by disruptive technology is a key responsibility of a Client Excellence Manager at PRMA Consulting. In this update, Sarah Forrest describes how her customer focus and agility enables biopharma clients to feel like they are winning in a digital world.

CAR-T therapy: the future begins to take shape

This on-demand webinar reviews the early experiences of the first CAR-T products to be licensed, enter into pricing and reimbursement (P&R) processes, and move towards delivery in a commercial setting.

Overcoming the market access challenges associated with high-cost combination therapies

The scale and potential impact of high-cost combinations coming to market in the next 2-3 years will force a significant change in pricing and reimbursement policies. Steve Fountain evaluates some of market access challenges for pharmaceutical manufacturers using insights gained from the PRMA Innovative Pricing Panel.

Free eBook: how to accelerate the generation of simultaneous, high-quality HTA submissions

How to accelerate the generation of simultaneous, high-quality health technology assessment (HTA) submissions. An introduction to the PRMA Navigator^®, a breakthrough HTA digital application.

Critically evaluating pricing and access risks and opportunities for an asset under different clinical development scenarios

Developing an international market access strategy to optimize pricing and reimbursement opportunities

Managed entry agreements: lessons from EU5

This on-demand webinar reviews the learnings on managed entry agreements in the EU5 and case studies of innovative approaches.

ISPOR Europe 2019

Digitalizing your market access processes will leave you wondering how you managed the “old way” for so long

How digital technology is transforming market access in the Asia-Pacific region

Where pharmaceutical market access is broader than formal payer assessments, for example in many Asia-Pacific markets, we have developed robust value assessment frameworks that integrate into the PRMA Healthcheck® digital application. This case study from a leading pharmaceutical manufacturer explains how the PRMA Healthcheck® has helped the organization to: assess market access and commercialization risks …

Do your global value dossiers contain these 5 common omissions?

Within the health technology assessment process, effective communication of global strategy and product value to affiliate teams is crucial.

Developing an economic model to optimize market access opportunities

Development of a value story, GVD, and payer materials

Orphan drug re-assessments in Germany: the impact on additional benefit and price

In Germany, the additional benefit (AB) of orphan drugs with annual sales below €50 mn is deemed proven by the marketing authorization. The G-BA determines only the extent of AB, from abbreviated submissions. However, when annual sales exceed €50 mn, a re-assessment is triggered, requiring a full submission followed by price re-negotiations with the GKV-Spitzenverband. …

Do market access withdrawals impact patient access to treatment in Germany?

In this new market access study, Anja Pownell, explores the impact of G-BA resolutions and subsequent market withdrawals on access to treatments for patients. In Germany, the G-BA determines the additional benefit (AB) of new therapies relative to the appropriate comparator therapy (ACT). For products without a (proven) AB, annual therapy costs cannot exceed those …

Watch and vote in the 2019 Health Economics Innovation Series

We are proud to announce that the PRMA Navigator® digital application has been shortlisted for the 2019 Health Economics Innovation Webinar Series: big ideas accelerating change in health economic and outcomes research (HEOR), real-world evidence (RWE), market access (MA), and health technology. The smarter digital market access solution for pharmaceutical and biotechnology clients The 2019 …

Mapping patient involvement in NICE appraisals of oncology products

Understanding the value of patient involvement is crucial to efforts to encourage patients and their representatives to participate in health technology assessment (HTA). This study sought to understand the extent of patient involvement in oncology single technology appraisals (STAs) by NICE, and the key issues that patients focus on. STA committee papers for oncology indications …

Future proofing for the 2020s market access trends

This on-demand webinar discusses the emerging trends in marketing access and anticipates how successful pharmaceutical and biotechnology manufacturers will prepare for competitively advantageous product launches in the early 2020s. 

Nathan White joins PRMA Consulting

Go-to market access consultancy, PRMA Consulting, is pleased to announce the appointment of Nathan White as Senior Director. Nathan’s professional experience, spanning nearly 2 decades in the pharmaceutical and biotech arena, is concentrated in US managed markets, global market access, specialty pharmacy, patient access programs, strategic consulting and communications, and insights generation. He has expertise …

Toby Gosden joins PRMA Consulting

PRMA Consulting is delighted to welcome Toby Gosden to the role of Director at PRMA Consulting. As part of its growth strategy, Toby will support the company’s mission to be the go-to consulting partner, delivering smarter market access solutions using insight-based strategic consultancy and transformative digital applications. Toby has more than 20 years’ experience in …

Digital innovation empowers global teams and local affiliates to shorten the time to market access

Digitally transforming health technology assessment (HTA) submission processes

61st ASH Annual Meeting and Exposition

Digitalizing your market access processes will leave you wondering how you managed the “old way” for so long In recent years, healthcare has gone digital: from artificial-intelligence-driven diagnostics, through to wearable technology and health apps. The pharmaceutical industry has also embraced digital efficiencies relating to internal processes, from drug discovery to drug development and packaging.Arguably, …

Estimating the eligible patient population for a targeted oncology therapy

EUnetHTA joint clinical assessments: where have we come from and where are we going?

This on-demand webinar explains the evolution of EUnetHTA and its influence to date on EU market access, and outlines the scenarios for the future development of this initiative.

The Fierce Innovation Award identifying outstanding innovation in Life Sciences

The Fierce Innovation Report featuring the PRMA Navigator® digital application: driving high-quality, simultaneous HTA submissions Led by the publisher of FierceBiotech and FiercePharma, the Fierce Innovation Report for Life Sciences identifies outstanding innovation that is driving improvements and transforming our industry.The latest innovative technologies that make the greatest impact for biotech and pharma companies are …

Finalist in the HealthEconomics.com’s 1st Annual HEOR and RWE Innovation Webinar Series: the PRMA Navigator^®

Digital transformation of HTA submission strategy with the PRMA Navigator^®, finalist in the HealthEconomics.com HEOR and RWE Innovation Webinar Series

Payer insight: 5 ways to get the most from your advisor interactions

Everyone in pharmaceutical market access is looking to get the most out of advisor interactions. This can’t be entered into lightly; the right blend of minds will lead to meaningful payer insight, actionable feedback, and advice. If you are working in pharmaceutical market access, you’ll be familiar with these challenges: How do you get early …

This top-5 pharma company chose the PRMA Navigator® to accelerate the generation of simultaneous HTA submissions and achieve up to 80% auto-population of their first drafts

Managed entry agreements: theory and principals

Managed entry agreements: theory and principles

Managed entry agreements: learnings for successful development from a UK perspective

A recent meeting of complex pricing experts from across the EU5 countries (France, Germany, Italy, Spain, and the UK) focused on the variability among countries of payers’ and policy-makers’ attitudes to managed entry agreements (MEAs), and the practical challenges for implementation capable of satisfying a range of country requirements. Here we summarize the insights from …

How to identify the potential for commercial success in early-stage product development

In early-phase value-driven development, it’s never too early to start thinking about commercial success. The PRMA Healthcheck® digital application will help you develop your strategic rationales at this critical .   The PRMA Healthcheck® assessments of early-phase assets help you to identify the potential for commercial success and shape direction and strategy at the earliest …

The influence of the patient voice in regulatory and health technology assessment activities

In the second of her two-part series, Sarah Richard explores a patient-centric approach to market access.

Accelerate the time to patient access with the PRMA Navigator^®

The PRMA Navigator^® digital application is accelerating the simultaneous generation of high-quality HTA submissions to allow patients faster access to new therapies. 

Transforming value and access outcomes in the Asia-Pacific region

Transforming value and access outcomes in the Asia-Pacific region

Are you in touch with the latest payer thinking?

Anja Pownell, Associate Director at PRMA Consulting, looks at how technology is putting dynamic payer thinking at the fingertips of its users. You partner with leading pharmaceutical and biotechnology manufacturers on their market access projects. What challenges do you most commonly see? In some disease areas, payer and health technology assessment (HTA) expectations are changing …

The things you need to know about the digital transformation of primary research

In the rapidly evolving market access landscape, it’s important to quickly identify current payer perspectives to determine future trends. High-quality, rapid primary research can be key to fast-forwarding your strategy. Sophie Clayton-Welch, Head of the International Experts Group at PRMA Consulting, discusses 3 ways that new technology is helping market access professionals gain cost-effective, real-time …

Digitization in primary research: a smart addition to traditional market access research methods

With 20 years’ experience working in primary research with payers and advisors, Sophie Clayton-Welch explains how digital transformation is helping clients gain rapid insights and competitive, market access advantage. What’s your role and background in primary research for market access? I’m the PRMA Consulting Head of the International Experts Group. We build relationships with key …

How to drive payer submission readiness for your late-phase products

The PRMA Healthcheck® digital assessments of late-phase pharmaceutical assets help you to bring a clear understanding of the risks and opportunities in multiple markets based on current payer requirements. This collection of case studies from leading pharmaceutical manufacturers explains how the PRMA Healthcheck® helps organizations to: focus attention on the key issues that will impact …

Healthcheck assessment for novel asset in moderate to severe rheumatoid arthritis

Proactively managing HTA challenges for follow-on indications in an orphan disease

How a leading pharma company gained significant market access insights prior to launch

This ebook explores how a leading pharmaceutical company gained an in-depth understanding of the latest payer thinking across rapidly evolving global markets.

Driving market access success in the US

Pharmaceutical market access requirements vary greatly by payer archetype in the US.

Market access roadmap in hemophilia B

PRMA Consulting expands its US presence

The go-to consulting partner for pricing, reimbursement, and market access strengthens its dedicated support of US pharmaceutical manufacturers through its new central Philadelphia office.

Understanding the impact of the ESMO value framework and its revisions to existing and pipeline oncology assets

Emerging biomarker in a hemato-oncology indication

Up to 30% of global HTA template requirements may not be met by a traditional GVD

Payer insight: 5 ways to get the most from your advisor interactions

Everyone in pharmaceutical market access is looking to get the most out of advisor interactions. This can’t be entered into lightly; the right blend of minds will lead to meaningful payer insight, actionable feedback, and advice. In this market access update, Sophie Clayton-Welch shares some recommendations to help you get the most out of your …

Wellbeing at PRMA Consulting

There is an increasing awareness within corporate organizations of the importance of our emotional fitness. In this update, Christina Lawrence explains how PRMA Consulting is encouraging colleagues to consider the role that inner calm and inner strength can play in developing a happier, more engaged, motivated, resilient, and productive team. How did you evolve your …

COVID-19: how your market access can fly even when you are grounded

As the novel coronavirus (COVID-19) continues to spread around the world, is this an opportunity to re-think the way that market access specialists do business?

Home working: 6 tips for fostering team connectivity in times of distance and disruption

In this time of enforced ‘social distancing’ and ‘self-isolation’, it is easy to forget that there can be significant workplace benefits to stopping and slowing down.

Wherever we work, we work together

In these exceptional times we value everyone who dedicates themselves to our care and support, regardless of their own health. It is reassuring to know that healthcare professionals, manufacturers, and colleagues, wherever they are, are working together to enable faster patient access to therapies that improve health outcomes. We are proud that across our network …

Reducing market access risk: how digital technology is strengthening strategies

Developing innovative pharmaceutical products is a lengthy process with no guarantee of success at the end. Manufacturers struggle with coordinating strategy internally and incorporating multiple payer requirements in clinical development programs. In this market access update, Dr William Aaron Grandy, Product Owner of Digital Applications at PRMA Consulting, explains how a digitally enabled assessment process …

Payer and HTA submissions: how digital technology is transforming market access processes

Claire Chadwick, HTA Manager at PRMA Consulting, explains how technology is helping market access professionals navigate the evolving challenges of HTA and payer submissions. What challenges do pharmaceutical and biotechnology market access professionals face when developing HTA and payer submissions? Successfully navigating HTA and payer submissions to achieve favorable pricing and access across multiple products …

WEConnect: Connecting Women’s Enterprises with Global Opportunities

  PRMA Consulting is proud to be a member of WEConnect: Connecting Women’s Enterprises with Global Opportunities global network. This recognizes our commitment to diversity and inclusion and our membership with organizations that share that commitment. WEConnect certifies women’s business enterprises based outside of the US that are at least 51% owned, as well as …

Breaking boundaries in market access: PRMA Consulting annual company meeting 2020

The theme for the PRMA Consulting annual company meeting 2020 was “Breaking Boundaries” and, aptly, it took place in Lisbon, Portugal, where explorers, such as Vasco De Gama and Ferdinand Magellan embarked on their voyages of discovery. The meeting truly captured the pioneering spirit that has helped our organization develop into an international consultancy that …

Navigating the updated 2020 ICER value assessment framework

In this webinar, US subject matter experts will provide an overview of changes in the recent update to the ICER value assessment framework (VAF), released in January 2020.

How collaboration and connectivity can accelerate payer submissions and drive faster patient access

Sotiria Papanicolaou explains how the combination of digital innovation and expert insight is removing roadblocks and speeding up the generation of payer submissions for pharma. The road to health technology assessment (HTA) and payer submissions is paved with complexity. Pharma’s mission is simple: to minimize the time between regulatory approval and market access, ensuring in …

Digital transformation: shaping the future of market access

In this update on digital transformation in market access, Dr William Aaron Grandy, Product Owner of Digital Applications at PRMA Consulting, asks what could tomorrow look like?

ICER 2020 value assessment framework: 7 updates that market access professionals need to understand

In this market access report, Nicole Lodowski provides an overview of the ICER value assessment framework and explains the 7 key areas that have been updated in 2020. The Institute for Clinical and Economic Review (ICER) is an independent healthcare research organization in the US. ICER evaluates the clinical and economic value of prescription drugs, …

Why on-demand insight is key to successful payer submissions

In the digital age, on-demand innovation is changing the way we live – redefining everything from how we watch TV to how we pay our bills. It’s also setting new expectations in the workplace, transforming the way we access and share data, and helping organizations collaborate and make better-informed decisions. With ‘anytime, anywhere’ access to …

The evolution of the PRMA Healthcheck^® for US payer archetypes

The PRMA Healthcheck® digital application provides a systematic and robust assessment of the market access risks and opportunities for your assets, based on the treatment landscape and evolving payer needs. This session will introduce upcoming changes to the PRMA Healthcheck® application from a US perspective.

Preparing for ICER assessments: key recommendations for manufacturers

In this free market access whitepaper, Nicole Lodowski, Principal at PRMA Consulting, explains how pharmaceutical and medical device manufacturers can prepare for the ICER assessment process.

Completing the puzzle: market access in Asia-Pacific

The Asia-Pacific (APAC) region may be the world’s second-largest pharmaceutical market – but it’s also one of the most complex when it comes to market access. In the major Asian markets – such as China, Japan, Singapore, and South Korea – policy isn’t just diverse, it changes rapidly. Moreover, with very little information in the …

Digital transformation in market access: don’t get lost in translation

Digital transformation is shaping the future of market access. Across all business sectors, technology is changing the way organisations interact with internal and external stakeholders, providing faster access to information and more efficient global collaboration. For pharma, the opportunity to transform market access through digital innovation is significant. However, getting there isn’t simply about optimising …

Why understanding payer archetypes is key to US market access

Until recently, pharma’s biggest market access challenge in the US has been learning to navigate “known unknowns”. Suddenly, however, long-standing unknowns – like the future of the Affordable Care Act, the nature of pricing reforms, or the influence of the Institute for Clinical and Economic Review (ICER) – are being set in a whole new …

PRMA Healthcheck^® for assets in early stages of clinical development

The PRMA Healthcheck® digital application provides a systematic and robust assessment of the market access risks and opportunities for your assets, based on the treatment landscape and evolving payer needs.

How will Covid-19 shape the evidence assessed by payers and HTA decision-makers?

As the Covid-19 pandemic continues to affect the health and economic climate, pharmaceutical manufacturers are focused on ensuring that they can deliver clinical trial results that support regulatory approval while minimizing or avoiding delays in the approval process. Although regulators have been issuing guidance on Covid-19, the consequences for health technology assessment (HTA) have not …

PRMA Healthcheck^® for assets in early stages of clinical development

The PRMA Healthcheck® digital application provides a systematic and robust assessment of the market access risks and opportunities for your assets, based on the treatment landscape and evolving payer needs.

Transform your market access in Asia-Pacific

The Asia-Pacific region is critical to the future growth plans of pharmaceutical manufacturers and PRMA Consulting are leading ground-breaking market access projects in the region.

PRMA Consulting announces its new office opening in Singapore

Jayne Sykes, Partner at PRMA Consulting, announces a new office opening in Singapore and explains how the company is shaping the future of market access for clients in the Asia-Pacific region. I am delighted to announce the opening of our first Asia-Pacific office in Singapore. It is an important step towards realizing improved market access …

Co-creation of a value assessment framework for early assets in the Asia-Pacific region​

Assessment framework of access landscape, reimbursement, and development plan for early pipeline assets

Framework to assess the early commercial and market access potential of an asset

Partnership with client’s Asia-Pacific team on regional activity and evidence roadmaps

CMS releases its annual IPPS final rule: key updates for manufacturers

On September 2, 2020, CMS released its annual Inpatient Prospective Payment System (IPPS) final rule, which applies to hospital discharges occurring on or after October 1, 2020 and will impact approximately 3,200 acute care hospitals across the US. While the ruling is made up of enormous detail across a 2,160-page document, there are several key …

PM Society Digital Awards: market access award winner

We are pleased to announce that the PRMA Healthcheck® digital application, a unique and innovative market access solution, has been chosen as the silver award winner in the market access category of the PM Society Digital Awards. The prestigious PM Society Digital Awards competition invites entries from organizations across the globe that deliver meaningful outcomes …

Cornerstones of ‘fair’ drug coverage: ICER and OHE release new white paper

On 28 September 2020, the Institute for Clinical and Economic Review (ICER), in collaboration with researchers at the Office of Health Economics (OHE) in the UK, published a new white paper: Cornerstones of ‘Fair’ Drug Coverage: Appropriate Cost-Sharing and Utilization Management Policies for Pharmaceuticals. The aim of the paper was to examine whether specific cost-sharing …

Driving market access readiness in the US through a unique digital application

What US market access teams should know about digital transformation.

Transforming your market access in Asia-Pacific

The Asia-Pacific region is critical to the future growth plans of pharmaceutical manufacturers and PRMA Consulting are leading ground-breaking market access projects in the region. These slides are from our on-demand webinar “Transform your market access in Asia-Pacific” where regional market access experts offer recommendations for: Assessing market access and commercialization risks, opportunities, and evidence needs …

Digital technology is transforming market access, but insight has a human heartbeat

It’s often said that foresight is the key to business success. That’s certainly true in the pharmaceutical industry, where anticipating evidence requirements early in a drug’s clinical development can be instrumental in securing optimal market access further down the line at launch. The foundations of successful market access strategies are typically laid in Phase 3 …

Meet our latest market access colleagues in Asia-Pacific

We are pleased to welcome three new colleagues to our international consultancy team. Xin, Ye, and Kin bring years of life-science expertise and a commitment to delivering smarter market access solutions for clients with an Asia-Pacific (APAC) focus.   Please join us in welcoming:  Xin Zhao, Consultant What do you do at PRMA Consulting and …

The PRMA Healthcheck^®: the future of market access in Asia-Pacific

The PRMA Healthcheck® digital application provides a systematic, robust, and consistent approach to analyzing the many factors that influence pricing, reimbursement, and market access in the Asia-Pacific region.

Take your market access to the next level: your free digital transformation eBook

Taking the mystery out of digital transformation: an enlightening collection of articles, case studies, and on-demand webinars for market access professionals.

Market access in Asia-Pacific: key challenges for manufacturers

In this market access update, Kin Cheng summarizes key pharmaceutical and biotechnology market access challenges across countries in Asia-Pacific. The internal and external considerations for manufacturers to accelerate time to market access in the region are also highlighted. Market access is evolving at a different pace in countries across the Asia-Pacific (APAC) region. Here we …

Recommendations for driving your journey to digital excellence

This free, 15-minute webinar provides key recommendations for manufacturers seeking to confidently fuel their strategies and drive stronger market access outcomes leveraging the experience and digital solutions of PRMA Consulting.